February 7th 2025
"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.
MPS2 test validated for detection of high-grade prostate cancer in non-DRE urine
January 30th 2025“MPS2 could potentially improve the health of our patients by avoiding overdiagnosis and overtreatment and allowing us to focus on those who are most likely to have aggressive cancers," says Ganesh S. Palapattu, MD, FACS.
Clarifying coding for percutaneous nephrolithotomy procedures
January 27th 2025"From a coding standpoint and from the work performed and valuation of the work and descriptors, it is appropriate to report the dilation (50436 without or 50437 with new access as appropriate) along with the nephrolithotomy codes (50080/50081) when both are performed at the same time by the same provider," write Jonathan Rubenstein, MD, and Mark Painter.
How to bill for placement of a peri-rectal spacer
January 24th 2025"Please note that although this starts out as a balloon rather than just the injection of a biodegradable product, this device is actually fully biodegradable and is absorbed within 6 months of insertion," write Jonathan Rubenstein, MD, and Mark Painter.
FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer
January 24th 202564Cu-SAR-bisPSMA was previously granted a fast track designation in August 2024 for PET imaging of PSMA-positive prostate cancer lesions in patients with suspected metastasis who are candidates for initial definitive therapy.
Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
January 22nd 2025"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.